

CIN: L15142RJ1991PLC006353

SARDA PROTEINS LTD.

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001 (Maharashtra)

Date: 05th August, 2022

(BY BSE LISTING CENTRE)

Sub: Outcome of the Board Meeting held on Friday, 05th August, 2022 pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

Ref.: Sarda Proteins Ltd, Scrip Code: 519242, Security ID: SRDAPRT.

Dear Sir/Ma'am,

The Board of Directors of the Company in their meeting held on Friday, 05th August, 2022 at the Corporate Office of the company situated at Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan) which commenced at 12:00 P.M. and concluded at 01:45 P.M. *inter-alia*, transacted the following business:

1. Approved the Un-audited Financial Results of the company for the quarter ended on 30th June, 2022 and took on record the Limited Review Report thereon. (Enclosed as Annexure-A)
Further, the extract of the Un-audited Financial Results would also be published in the newspapers in compliance with Regulation 47 of Listing Regulations.
2. Approved convening of 31st Annual General Meeting ("AGM") of the Company on Friday, the 23rd Day of September, 2022 at 12:30 P.M. through Video Conferencing ("VC")/Other Audio Visual Means ("OAVM") and matters connected therewith.
3. Approved the closure of Register of Members and Share Transfer Books of the Company from Saturday, 17th September, 2022 to Friday, 23rd September, 2022 (both days inclusive) for the purpose of 31st Annual General Meeting.
4. Approved the Board's Report and annexures thereof for the financial year 2021-22.

TRADING WINDOW:


Further in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Company's code of conduct for Prohibition of Insider Trading the "Trading Window" for trading in the shares of the Company will open from Monday, 08th August, 2022 for all Designated Persons and their relatives.

You are requested to kindly take the same on record.

Thanking you,
Yours faithfully,

FOR SARDA PROTEINS LTD

For SARDA PROTEINS LTD

AMIT KUMAR MODI  Company Secretary
COMPANY SECRETARY &
COMPLIANCE OFFICER
M.NO.: A29371

Encl: a/a

Reg. Office: B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan)
Corp. office: Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan)
Contact No.: +91-7737822222; E Mail: sardaproteins@yahoo.com; Web: www.sardaproteins.com

SARDA PROTEINS LIMITED

Reg. Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)
Phone: +91 7737822222, EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com
CIN: L15142RJ1991PLC006353

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED 30TH JUNE 2022

Rs.in Lakhs

Particulars	Three Months Ended on	Preceding Three Months Ended on	Corresponding Three Month	Year Ended
	30.06.2022	31.03.2022	30.06.2021	31.03.2022
	Un-Audited	Audited	Un-Audited	Audited
I. Revenue from operations	-	657.64	69.76	1,075.98
II. Other Income	5.17	0.97	2.10	8.54
III. Total Revenue (I+II)	5.17	658.61	71.86	1,084.52
IV. Expenses:				
Cost of Material Consumed		-	-	-
Purchase of Stock -in- Trade	-	618.29	69.75	1,028.63
Changes in Inventories (Finished Goods, WIP, Stock-in-Trade)		-	-	-
Employee Benefit Expenses	3.44	2.54	3.68	12.57
Finance Cost		-	-	0.02
Depreciation and Amortisation Expenses	1.51	(0.01)	0.02	0.05
Other expenses		7.73	-	7.73
Total Expenses (IV)	4.95	628.55	73.45	1,049.00
V. Profit/(Loss) before Exceptional and Extraordinary Items and Tax (III-IV)	0.22	30.06	(1.59)	35.52
VI. Exceptional Items		0.24	-	0.24
VII. Profit/(Loss) before Extraordinary Items and Tax (V-VI)	0.22	29.82	(1.59)	35.28
VIII. Extraordinary Items		-	-	-
IX. Profit/(Loss) before Tax (V-VI)	0.22	29.82	(1.59)	35.28
X. Tax Expense				
(1) Current Tax		-	-	-
(2) Deferred Tax		4.53	-	4.53
XI. Profit/(Loss) for the period from Continuing Operations (VII-VIII)	0.22	25.29	(1.59)	30.75
XII. Profit/(Loss) from Discontinued Operations	-	-	-	-
XIII. Tax Expenses of Discontinued Operations	-	-	-	-
XIV. Profit/(Loss) from Discontinued Operations (after tax) (X-XI)	-	-	-	-
XV. Profit/(Loss) for the period (IX+XII)	0.22	25.29	(1.59)	30.75
XVI. Other Comprehensive Income				
A (i) Items will not be reclassified to Profit or Loss	-	-	-	-
(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-
B (i) Items will be reclassified to Profit or Loss	-	-	-	-
(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-
XVII. Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and other comprehensive income for the period)	0.22	25.29	(1.59)	30.75
Paid up Equity Share Capital (Face Value of the Share-Rs. 10 Per Share)	172.59	172.59	172.59	172.59
XVIII. Earnings per Equity Share				
(1) Basic	0.01	1.47	(0.09)	1.78
(2) Diluted	0.01	1.47	(0.09)	1.78

Notes:

- The above results were approved by Audit Committee and Board of Directors in their meeting held on 05th August, 2022.
- Equity Share Capital includes Rs. 77.86 Lakhs as Share Forfeiture Account.
- Segment Results as per AS is not applicable, as company dealing in only one segment i.e. "Agro Products".
- No Investor Complaints were received during the quarter ended 30-Jun-2022 nor any pending as on 01-Jul-2022.
- Figures for the previous period have been regrouped wherever considered necessary so as to confirm to the classification of the current period.



on behalf of the Board
Sarda Proteins Ltd

Deepak Data (DIN: 01672415)
Managing Director

Place: Jaipur
Date: 05th August, 2022

UDIN: 22072854AOIN445995



Khetawat Agarwal & Co.
Chartered Accountants

Limited Review Report
Unaudited Standalone Quarterly Results


To
The Board of Directors
Sarda Proteins Ltd

We have reviewed the accompanying statement of unaudited financial results of **SARDA PROTEINS LTD** for the Quarter ended on 30th June, 2022. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Khetawat Agarwal & Co.
Chartered Accountants
FRN: 003960C


M.L. Agarwal
Partner
M. No.: 072854

UDIN : 22072854AOINVY5995

Place : Jaipur
Date : 05.08.2022